Standard Standard

Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. / Sandoo, A.A.; Kitas, G.; Dimitroulas, T. et al.
In: International Journal of Cardiology, Vol. 172, No. 1, 10.01.2014, p. 285-286.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

Sandoo, AA, Kitas, G, Dimitroulas, T, Sandoo, A, Smith, JP & Kitas, GD 2014, 'Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis', International Journal of Cardiology, vol. 172, no. 1, pp. 285-286. https://doi.org/10.1016/j.ijcard.2013.12.235

APA

Sandoo, A. A., Kitas, G., Dimitroulas, T., Sandoo, A., Smith, J. P., & Kitas, G. D. (2014). Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. International Journal of Cardiology, 172(1), 285-286. https://doi.org/10.1016/j.ijcard.2013.12.235

CBE

Sandoo AA, Kitas G, Dimitroulas T, Sandoo A, Smith JP, Kitas GD. 2014. Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. International Journal of Cardiology. 172(1):285-286. https://doi.org/10.1016/j.ijcard.2013.12.235

MLA

VancouverVancouver

Sandoo AA, Kitas G, Dimitroulas T, Sandoo A, Smith JP, Kitas GD. Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. International Journal of Cardiology. 2014 Jan 10;172(1):285-286. doi: 10.1016/j.ijcard.2013.12.235

Author

Sandoo, A.A. ; Kitas, G. ; Dimitroulas, T. et al. / Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. In: International Journal of Cardiology. 2014 ; Vol. 172, No. 1. pp. 285-286.

RIS

TY - JOUR

T1 - Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis

AU - Sandoo, A.A.

AU - Kitas, G.

AU - Dimitroulas, T.

AU - Sandoo, A.

AU - Smith, J.P.

AU - Kitas, G.D.

PY - 2014/1/10

Y1 - 2014/1/10

N2 - Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) mortality and reduced life expectancy predominantly due to increased rates of acute coronary syndromes including unrecognized myocardial infractions [1]. The increased CV burden in this population has prompted rheumatologists and cardiologists to a more early and vigilant screening for CV risk stratification even in asymptomatic patients. Asymmetric dimethylarginine (ADMA) and subendocardial viability ratio (SEVR) represent non-invasive methods of assessing endothelial dysfunction and coronary microvascular perfusion to subendocardium respectively, two pivotal players in the development of CV disease and myocardial ischemia

AB - Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) mortality and reduced life expectancy predominantly due to increased rates of acute coronary syndromes including unrecognized myocardial infractions [1]. The increased CV burden in this population has prompted rheumatologists and cardiologists to a more early and vigilant screening for CV risk stratification even in asymptomatic patients. Asymmetric dimethylarginine (ADMA) and subendocardial viability ratio (SEVR) represent non-invasive methods of assessing endothelial dysfunction and coronary microvascular perfusion to subendocardium respectively, two pivotal players in the development of CV disease and myocardial ischemia

U2 - 10.1016/j.ijcard.2013.12.235

DO - 10.1016/j.ijcard.2013.12.235

M3 - Article

VL - 172

SP - 285

EP - 286

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -